Skip to main content
. 2010 Mar 24;91(5):1377–1386. doi: 10.3945/ajcn.2009.28923

TABLE 4.

Association between MAT1A haplotypes and hypertension, stroke, and cardiovascular disease (CVD) in the Boston Puerto Rican Health Study

Stroke1
 Hypertension2
 CVD3
Haplotype4 Frequency Odds ratio 95% CI P value5 Odds ratio 95% CI P value5 Odds ratio 95% CI P value5
G-G-G 0.37 1.62 0.77, 3.42 0.203 1.31 0.94, 1.81 0.109 1.31 0.88, 1.93 0.174
A-G-A 0.27 0.84 0.40, 1.76 0.648 1.00 0.72, 1.38 0.975 1.01 0.69, 1.48 0.975
A-A-G 0.26 0.27 0.11, 0.65 0.003 0.63 0.46, 0.87 0.005 0.58 0.39, 0.86 0.007
A-G-G 0.07 0.46 0.10, 2.05 0.310 0.92 0.53, 1.57 0.752 0.73 0.36, 1.47 0.380
G-G-A 0.03 1.83 0.51, 6.61 0.358 1.24 0.59, 2.57 0.572 2.30 1.15, 4.60 0.018
1

MAT1A haplotypes were associated with stroke at a global significance of P = 0.001, or P = 0.002 after a permutation test.

2

MAT1A haplotypes were associated with hypertension at a global significance of P = 0.012, or P = 0.020 after a permutation test.

3

MAT1A haplotypes were associated with CVD (heart attack was excluded) at a global significance of P = 0.018, or P = 0.025 after a permutation test.

4

MAT1A haplotypes were estimated based on 3 single nucleotide polymorphisms in the following order: i15173, 3U1510, and d18777.

5

P values were calculated by logistic regression models and adjusted for MTHFR genotype, age, sex, BMI, smoking, alcohol use, physical activity, medication use for depression and type 2 diabetes, population admixture, and plasma concentrations of vitamin B-6, vitamin B-12, folate, and creatinine.